Alphaligo 125 mg Tablet is a Health Canada–registered human drug (DIN 02233817) held by Clinique Lafontaine Inc, Division Les Importations Ortho, containing Phosphorus (Sodium Phosphate). Health Canada lists its status as Cancelled Post Market (status date 07 Aug 2008). Nexara Health has matched 34 registrations of Phosphorus (Sodium Phosphate) across 7 other regulated markets.
Health Canada registration
| DIN | 02233817 |
|---|---|
| Brand name | Alphaligo |
| Active ingredient | Phosphorus (Sodium Phosphate) |
| Strength | 125 mg |
| Dosage form | Tablet |
| Route | Oral |
| Company | Clinique Lafontaine Inc, Division Les Importations Ortho |
| Status | Cancelled Post Market — 07 Aug 2008 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Phosphorus (Sodium Phosphate) registered in other markets
34 registrations of the same molecule in 7 national registries outside Canada (first 19 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Australia | Phosphate Phebra | Fg | Tablet, compound effervescent, equivalent to 500 mg phosphorus | GE | PBS | |
| Australia | Phosphate Phebra | Fg | Tablet, compound effervescent, equivalent to 500 mg phosphorus | GE | PBS | |
| Czech Republic | Phosphorus | — | 3CH-30CH | Gra | R | SUKL DLP |
| Finland | Phosphorus | Circlum Farmasia Oy | C6, C12, C30, C200, M, XM | pilleri | Rekisteröinti myönnetty | Fimea Perusrekisteri |
| Finland | Phosphorus | DCG Nordic AB | D6,D12,D30,D200,M,CM | pilleri | Rekisteröinti myönnetty | Fimea Perusrekisteri |
| Netherlands | Phosphorus | BOIRON (Messimy) | 6 DH t/m 60 DH#3CH t/m 200 CH#6 K t/m 100.000 K#2 LM t/m 30 LM | Uitsluitend apotheek of drogist | EU national register | |
| Netherlands | Phosphorus | BOIRON (Messimy) | 6 DH t/m 60 DH#3 CH t/m 200 CH#6 K t/m 100.000 K#2 LM t/m 30 LM | Globuli | Uitsluitend apotheek of drogist | EU national register |
| United Arab Emirates | Phosphorus Boiron | BOIRON, France, Messimy | 4 DH - 200 CH | Pillules | Active | EDE |
| United Kingdom | Phosphorus 30c homeopathic pillules | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Phosphorus 30c homeopathic tablets | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Phosphorus 6c homeopathic tablets | — | 0001 | NHS dm+d VMP | ||
| United States | Bestmade Natural Products Phosphorus | Bestmade Natural Products | Tablet, Soluble | listed | FDA NDC | |
| United States | BM Phosphorus | BM Private Limited | Globule | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC | |
| United States | Phosphorus | Boiron | Pellet | listed | FDA NDC |
See every manufacturer of Phosphorus (Sodium Phosphate) worldwide →
Regulator price references for Phosphorus (Sodium Phosphate)
Published list or reimbursement prices for Phosphorus (Sodium Phosphate) presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Australia | Phosphate Phebra | Tablet, compound effervescent, equivalent to 500 mg phosphorus | 63.59 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Australia | Phosphate Phebra | Tablet, compound effervescent, equivalent to 500 mg phosphorus | 63.59 AUD | ex-manufacturer | PBS | 2026-09-08 |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Alphaligo (DIN 02233817) marketed in Canada?
No. Health Canada lists DIN 02233817 as Cancelled Post Market as of 07 Aug 2008.
Who holds the Canadian licence for this product?
Clinique Lafontaine Inc, Division Les Importations Ortho is the company of record in the Health Canada Drug Product Database.
Is Phosphorus (Sodium Phosphate) registered outside Canada?
Yes — Nexara Health has matched 34 registrations in 7 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02233817, status date 2008-08-07; national medicine registries: EDE, EU national register, FDA NDC, Fimea Perusrekisteri, NHS dm+d VMP, PBS, SUKL DLP; price sources: PBS. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02233817, status date 2008-08-07; national medicine registries: EDE, EU national register, FDA NDC, Fimea Perusrekisteri, NHS dm+d VMP, PBS, SUKL DLP; price sources: PBS.
Health Canada Drug Product Database (DPD), DIN 02233817, status date 2008-08-07; national medicine registries: EDE, EU national register, FDA NDC, Fimea Perusrekisteri, NHS dm+d VMP, PBS, SUKL DLP; price sources: PBS. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.